September 5, 2013 — ITC Nexus Holding Co., a company in hemostasis management and point-of-care (POC) testing, announced it has acquired Accumetrics, a specialist in assessing patient response to all major antiplatelet therapies. Terms of the transaction were not disclosed.

HeartWare International Inc. announced that the U.S. Food and Drug Administration (FDA) has approved an IDE (Investigational Device Exemption) Supplement that allows HeartWare to commence enrollment in an additional patient cohort for ENDURANCE, the company's pivotal, destination therapy clinical study.

 

Terumo has introduced the GlideSheath Slender Hydrophilic Introducer Sheath, a 6 French sheath that has the outer diameter of a 5 French sheath. Its narrower profile makes it optimal for radial access, especially in women with smaller radial access.

C. R. Bard Inc. has entered into a definitive merger agreement to acquire Rochester Medical Corp. at a price of $20 per share, or approximately $262 million in the aggregate. The Rochester Medical board of directors unanimously approved the agreement and will recommend that the company's shareholders approve the transaction.

 
 

Based on its recent analysis of the cardiology informatics market, Frost & Sullivan recognizes Ascend HiT with the 2013 North America Frost & Sullivan Award for Customer Value Leadership. With the introduction of CardioAnalytics, Ascend has proved that it is at the vanguard of the cardiology market's efforts to enhance quality and analytics. This product complements and extends the best-of-breed Ascend CV reporting products, and in the process, positions the company to deliver one of the most crucial elements of the cardiology value chain—cardiovascular procedural reporting.


September 3, 2013 — St. Jude Medical Inc. announced the CE mark approval of its next-generation EnligHTN renal denervation system for treating patients with drug-resistant, uncontrolled hypertension. The EnligHTN system was display during the 2013 European Society of Cardiology (ESC) meeting Aug. 31 to Sept. 3.


Subscribe Now